PDE10A and ovarian neoplasm: Our findings are clinically relevant as they reveal that high expression of PDE10A in ovarian tumors correlates with significantly worse overall survival for patients and with upregulation of various oncogenic pathways, including Wnt and MAPK signaling, in the tumor microenvironment.